{"id":56983,"date":"2026-02-12T21:30:05","date_gmt":"2026-02-12T13:30:05","guid":{"rendered":"https:\/\/flcube.com\/?p=56983"},"modified":"2026-04-21T20:47:03","modified_gmt":"2026-04-21T12:47:03","slug":"hengruis-trastuzumab-rezetecan-wins-eighth-btd-for-first-line-her2-nsclc-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56983","title":{"rendered":"Hengrui\u2019s Trastuzumab Rezetecan Wins Eighth BTD for First-Line HER2+ NSCLC in China"},"content":{"rendered":"\n

Jiangsu Hengrui Pharmaceuticals Co., Ltd.<\/strong> (SHA:\u202f600276<\/a>, HKG:\u202f1276<\/a><\/strong>) announced that trastuzumab rezetecan (SHR-A1811)<\/strong>, its HER2-targeted antibody-drug conjugate (ADC)<\/strong>, has been granted Breakthrough Therapy Designation (BTD)<\/strong> by the Center for Drug Evaluation (CDE)<\/strong> of NMPA<\/strong> for first-line locally advanced or metastatic NSCLC with HER2 (ERBB2) activating mutations<\/strong>. This marks the eighth BTD<\/strong> for the in-house developed ADC<\/strong>, which has rapidly accumulated breakthrough designations across seven additional indications<\/strong> since its initial NSCLC approval in May\u202f2025<\/strong>.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>Jiangsu Hengrui Pharmaceuticals (SHA:\u202f600276, HKG:\u202f1276)<\/td><\/tr>
Agency<\/strong><\/td>CDE\/NMPA (China)<\/td><\/tr>
Asset<\/strong><\/td>Trastuzumab rezetecan (SHR-A1811) \u2013 HER2-targeted ADC<\/td><\/tr>
New BTD<\/strong><\/td>First-line HER2-mutant NSCLC<\/strong> (locally advanced\/metastatic)<\/td><\/tr>
BTD Tally<\/strong><\/td>8 total breakthrough designations<\/strong><\/td><\/tr>
Prior BTD Indications<\/strong><\/td>Breast cancer, NSCLC (2L+), colorectal cancer, gastric\/GEJ adenocarcinoma, biliary tract cancer, primary peritoneal cancer, cervical cancer<\/td><\/tr>
First Approval<\/strong><\/td>May\u202f2025<\/strong> \u2013 HER2-mutant NSCLC (\u22651 prior systemic therapy)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

BTD Portfolio Expansion<\/h2>\n\n\n\n
Indication<\/th>BTD Status<\/th>Strategic Value<\/th><\/tr><\/thead>
First-line HER2+ NSCLC<\/strong><\/td>New (8th BTD)<\/strong><\/td>Front-line positioning<\/strong> vs. chemotherapy; largest addressable population<\/td><\/tr>
Breast cancer<\/strong><\/td>BTD granted<\/td>Competing with trastuzumab deruxtecan (Enhertu) in HER2+ and HER2-low<\/td><\/tr>
Colorectal cancer<\/strong><\/td>BTD granted<\/td>First HER2 ADC<\/strong> with BTD in this indication; filing under NMPA review<\/td><\/tr>
Gastric\/GEJ adenocarcinoma<\/strong><\/td>BTD granted<\/td>High HER2 prevalence; established HER2 therapy (trastuzumab) precedent<\/td><\/tr>
Biliary tract cancer<\/strong><\/td>BTD granted<\/td>Orphan indication; limited treatment options<\/td><\/tr>
Primary peritoneal cancer<\/strong><\/td>BTD granted<\/td>Rare gynecologic malignancy; unmet need<\/td><\/tr>
Cervical cancer<\/strong><\/td>BTD granted<\/td>HPV-related; potential combination with immunotherapy<\/td><\/tr>
Second-line+ HER2+ NSCLC<\/strong><\/td>Approved May\u202f2025<\/strong><\/td>First approved indication<\/strong>; foundation for first-line expansion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Positioning & Market Context<\/h2>\n\n\n\n
Factor<\/th>Strategic Analysis<\/th><\/tr><\/thead>
HER2-Mutant NSCLC Prevalence<\/strong><\/td>~2-4% of NSCLC patients<\/strong> (~20,000-40,000 annual cases in China); no approved HER2-targeted therapies in first-line<\/strong> globally<\/td><\/tr>
BTD Strategic Value<\/strong><\/td>Accelerated development and review<\/strong> (6-12 month timeline compression); priority CDE consultation<\/strong>; conditional approval pathway<\/strong> eligibility<\/td><\/tr>
Hengrui ADC Platform Validation<\/strong><\/td>Eight BTDs across solid tumors<\/strong> demonstrates broad mechanism applicability<\/strong> and regulatory confidence<\/strong> in SHR-A1811’s efficacy and safety profile<\/strong><\/td><\/tr>
Competitive Landscape<\/strong><\/td>Trastuzumab deruxtecan (Enhertu, AstraZeneca\/Daiichi)<\/strong> leads globally; Hengrui’s domestic manufacturing and pricing<\/strong> positions for China market leadership<\/strong> and emerging market expansion<\/strong><\/td><\/tr>
First-Line Opportunity<\/strong><\/td>Front-line positioning<\/strong> (vs. second-line approval) captures treatment-na\u00efve patients<\/strong> before chemotherapy resistance; premium pricing and volume potential<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Development & Commercial Outlook<\/h2>\n\n\n\n
Priority<\/th>Execution Plan<\/th>Timeline<\/th><\/tr><\/thead>
First-Line NSCLC<\/strong><\/td>Phase III registrational trial; BTD-enabled accelerated pathway<\/td>2026-2027<\/td><\/tr>
NRDL Inclusion<\/strong><\/td>Reimbursement negotiation for approved 2L+ indication; 1L+ filing preparation<\/td>2026<\/td><\/tr>
Global Expansion<\/strong><\/td>Ex-China partnership discussions; FDA\/EMA IND submissions<\/td>2026-2027<\/td><\/tr>
Pipeline Synergies<\/strong><\/td>Combination studies with Hengrui’s PD-1 inhibitors (SHR-1210) and angiogenesis inhibitors<\/td>2026+<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Forward\u2011Looking Statements<\/strong>
This brief contains forward\u2011looking statements regarding trastuzumab rezetecan first-line NSCLC approval timelines, BTD-enabled commercial acceleration, and competitive positioning vs. trastuzumab deruxtecan. Actual results may differ due to Phase III trial outcomes, pricing pressure from national procurement programs, and global partnership negotiation results.-Fineline Info & Tech<\/a><\/p>\n\n\n\n